Development and characterization of biodegradable nanospheres as delivery systems of anti-ischemic adenosine derivatives

Biomaterials

Volumn 26, Issue 11, 2005, Pages 1299-1306

  Dalpiaz, Alessandro ^a   Leo, Eliana ^b   Vitali, Federica ^a   Pavan, Barbara ^a   Scatturin, Angelo ^a   Bortolotti, Fabrizio ^a   Manfredini, Stefano ^a   Durini, Elisa ^a   Forni, Flavio ^b   Brina, Barbara ^b   Vandelli, Maria Angela ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Controlled drug release; N6 Cyclopentyladenosine; Nanoparticles; Polylactic acid; Pro drug; Stability

Indexed keywords

BIODEGRADATION; BLOOD; DIALYSIS; DRUG DOSAGE; EVAPORATION; HYDROLYSIS; MICROEMULSIONS; PRECIPITATION (CHEMICAL); SOLVENT EXTRACTION;

BIODEGRADABLE NANOSPHERES; GEL FILTERATION; NANOPRECIPITATION; ULTRACENTRIFUGATION;

NANOSTRUCTURED MATERIALS;

5' OCTANOYL CYCLOPENTYLADENOSINE; 6 N CYCLOPENTYLADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE DERIVATIVE; NANOPARTICLE; POLYLACTIC ACID; PRODRUG; RESOMER; SOLVENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIODEGRADABILITY; BLOOD; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIALYSIS; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; DRUG STRUCTURE; EMULSION; ENCAPSULATION; EVAPORATION; FEMALE; GEL FILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; INCUBATION TIME; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; ULTRACENTRIFUGATION;

ABSORBABLE IMPLANTS; ADENOSINE; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DELAYED-ACTION PREPARATIONS; DIFFUSION; DRUG CARRIERS; HUMANS; LACTIC ACID; METABOLIC CLEARANCE RATE; NANOTUBES; PARTICLE SIZE; POLYMERS; RECEPTOR, ADENOSINE A1; VASODILATOR AGENTS;

EID: 4744375408     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2004.04.033     Document Type: Article

References (33)

1. de Mendonca A., Sebastiao A.M., Ribeiro J.A. Adenosine. does it have a neuroprotective role after all? Brain Res Brain Res Rev. 33:2000;258-274
2. 1 receptor. analysis of the potential therapeutic effects obtained by its activation in the central nervous system Curr Med Chem. 9:2002;1923-1937
3. Fredholm B.B., Abbracchio M.P., Burnstock G., Daly J.W., Harden T.K., Jacobson K.A., Leff P., Williams M. Nomenclature and classification of purinoceptors. Pharmacol Rev. 46:1994;143-156
4. 1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders. Ann NY Acad Sci. 825:1997;23-29
5. Johansson B., Halldner L., Dunwiddie T.V., Masino S.A., Poelchen W., Gimenez-Llort L., Escorihuela R.M., Fernandez-Teruel A., Wiesenfeld-Hallin Z., Xu X.J., Hardemark A., Betsholtz C., Herlenius E., Fredholm B.B. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci USA. 98:2001;9407-9412
6. Muller C.E. Adenosine receptor ligands - recent developments part I. Agonists. Curr Med Chem. 7:2000;1269-1288
7. Hsu S.S., Newell D.W., Tucker A., Malouf A.T., Winn H.R. Adenosinergic modulation of CA1 neuronal tolerance to glucose deprivation in organotypic hippocampal cultures. Neurosci Lett. 178:1994;189-192
8. Newman G.C., Hospod F.E., Trowbridge S.D., Motwani S., Liu Y. Restoring adenine nucleotides in a brain slice model of cerebral reperfusion. J Cereb Blood Flow Metab. 18:1998;675-685
9. Simpson R.E., O'Regan M.H., Perkins L.M., Phillis J.W. Excitatory transmitter amino acid release from the ischemic rat cerebral cortex. effects of adenosine receptor agonists and antagonists J Neurochem. 58:1992;1683-1690
10. Von Lubitz D.K., Marangos P.J. Cerebral ischemia in gerbils. postischemic administration of cyclohexyladenosine and 8-sulfophenyl-theophylline J Mol Neurosci. 2:1990;53-59
11. Von Lubitz D.K., Lin R.C., Bischofberger N., Beenhakker M., Boyd M., Lipartowska R., Jacobson K.A. Protection against ischemic damage by adenosine amine congener, a potent and selective adenosine A1 receptor agonist. Eur J Pharmacol. 369:1999;313-317
12. Jacobson K.A., Trivedi B.K., Churchill P.C., Williams M. Novel therapeutics acting via purine receptors. Biochem Pharmacol. 41:1991;1399-1410
13. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 50:1998;413-492
14. Brodie M.S., Lee K., Fredholm B.B., Stahle L., Dunwiddie T.V. Central nervous peripheral mediation of responses to adenosine receptor agonists. evidence against a central mode of action Brain Res. 415:1987;323-330
15. Pavan B., Ijzerman A.P. Processing of adenosine receptor agonists in rat and human whole blood. Biochem Pharmacol. 56:1998;1625-1632
16. 6-cyclopentyladenosine in the rat. J Pharmacol Exp Ther. 268:1994;616-624
17. Maillard M.C., Nikodijevic O., LaNoue K.F., Berkich D., Ji X.D., Bartus R., Jacobson K.A. Adenosine receptor prodrugs. synthesis and biological activity of derivatives of potent, A1-selective agonists J Pharm Sci. 83:1994;46-53
18. 6-cyclopentyladenosine, a selective A1 receptor agonist. Pharm Res. 18:2001;531-536
19. 1 receptor agonist. J Control Rel. 73:2001;303-313
20. Dalpiaz A., Scatturin A., Pavan B., Biondi C., Vandelli M.A., Forni F. Poly(lactic acid) microspheres for the sustained release of antiischemic agents. Int J Pharm. 242:2002;115-120
21. Jalil R.U. Biodegradable poly(lactic) and poly(lactide-co-glycolide) polymers in sustained drug delivery. Drug Dev Ind Pharm. 16:1990;2353-2367
22. Townsend-Nicholson A., Shine J. Molecular cloning and characterisation of a human brain A1 adenosine receptor cDNA. Brain Res Mol Brain Res. 16:1992;365-370
23. Townsend-Nicholson A., Schofield P.R. A threonine residue in the seventh transmembrane domain of the human A1 adenosine receptor mediates specific agonist binding. J Biol Chem. 269:1994;2373-2376
24. Fessi H., Puisieux F., Devissaguet J.P., Ammoury N., Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm. 55:1989;R1-R4
25. Zambaux M.F., Bonneaux F., Gref R., Maincent P., Dellacherie E., Alonso M.J., Labrude P., Vigneron C. Influence of experimental parameters in the characteristics of poly(lactic acid) nanoparaticles prepared by a double emulsion method. J Control Rel. 50:1998;31-40
26. Childs C.E. Determination of polyoxyethylen glycol in gamma-globulin solutions. Microchem J. 20:1975;190-192
27. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal Biochem. 150:1985;76-85
28. 50) of an enzymatic reaction. Biochem Pharmacol. 22:1973;3099-3108
29. Dalpiaz A., Townsend-Nicholson A., Beukers M.W., Schofield P.R., Ijzerman A.P. Thermodynamics of full agonist, partial agonist, and antagonist binding to wild-type and mutant adenosine A1 receptors. Biochem Pharmacol. 56:1998;1437-1445
30. Kreuter J., Petrov V.E., Kharkevich D.A., Alayautdin R.N. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after 1st delivery across the blood-brain barrier using surfactant coded nanoparticles. J Control Rel. 49:1997;81-87
31. Calvo P., Gouritin H., Villarroya B., Eclancher F., Giannavola C., Klein C., Andreux J.P., Couvreur P. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rats. Eur J Neurosci. 15:2002;1317-1326
32. Govender T., Stolnik S., Garnett M.C., Illum L., Davis S. PLGA nanoparticles prepared by nanoprecipitation. drug loading and release studies of a water soluble drug J Control Rel. 57:1999;171-185
33. Barichello J.M., Morishita M., Takayama K., Nagai T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm. 25:1999;471-476